Among the group’s current objectives is the development and validation of tissue diagnostic tests to adjust the target patient population of antibody drug conjugates. Applying quantitative mass spectrometry to precision oncology, and improving stratification of patients for FGFR pathway inhibition through the development of combined preselection approaches. In addition, expanding the catalogues of molecular tests accredited by ISO15189.

Visit the research group’s page

Ponderació
9

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.